About Semaglutide
A long-acting GLP-1 receptor agonist studied for glycemic control and weight management.
Research dose ranges
- Dose: 250–2400 mcg per administration
- Frequency: 1× per day
- Route: subcutaneous
- Half-life: ~168 hours
- Cycle: 16 weeks on / 0 off
Clinical protocols escalate from 0.25 mg weekly to 2.4 mg weekly over 16 weeks to minimize gastrointestinal side effects.
Storage
Lyophilized vials at 2–8°C. Reconstituted, refrigerate and protect from light.